Promoted Content
Promoted Content

Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sotagliflozin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: SAR439954

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2021

            Details:

            The feedback was provided in response to a request made by Lexicon following the completion of the SOLOIST and SCORED studies relating to the potential submission of an NDA based on the results of such studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CardiAMP Cell Therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            Pivotal Phase 3 CardiAMP Heart Failure Trial aims to determine the safety and efficacy of CardiAMP cell therapy in the treatment of patients with ischemic heart failure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CardiAMP Cell Therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: BCDA-01

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            Helix Biotherapeutic Delivery System demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in journal Cardiovascular Revascularization Medicine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omecamtiv Mecarbil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 423

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cytokinetics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration November 23, 2020

            Details:

            Pursuant to the terms of the Agreement, upon the effective date of Amgen’s termination, research, development and commercialization rights for compounds, including omecamtiv mecarbil and AMG 594, will transition to Cytokinetics.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Treprostinil Sodium

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TreT

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: United Therapeutics

            Deal Size: $95.0 million Upfront Cash: $45.0 million

            Deal Type: Licensing Agreement November 19, 2020

            Details:

            This is the fourth development milestone brining it to $50M, under Mankind's licensing deal with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. MannKind will get low double-digit royalties on net sales of TreT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mavacamten

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million

            Deal Type: Acquisition November 17, 2020

            Details:

            Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact.